Keyphrases
Remission
100%
Rituximab
100%
Cyclophosphamide
100%
Thrombotic Thrombocytopenic Purpura
100%
ADAMTS13
66%
Plasma Exchange
33%
Intensive Immunosuppressive Therapy
33%
Prednisone
16%
Immunosuppressive Therapy
16%
Autoantibodies
16%
Cyclosporine
16%
University Medical Centre
16%
Splenectomy
16%
Older Women
16%
Autoimmune Process
16%
Design Case
16%
Autoimmune
16%
Metalloprotease
16%
Thrombotic Microangiopathy
16%
Clinical Remission
16%
ADAMTS13 Protein
16%
Hematologic Variables
16%
Recombinant ADAMTS13
16%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Rituximab
100%
Cyclophosphamide
100%
Thrombotic Thrombocytopenic Purpura
100%
Von Willebrand Factor Cleaving Proteinase
83%
Immunosuppressive Agent
33%
Disease
16%
Prednisone
16%
Ciclosporin
16%
Vincristine
16%
Metalloproteinase
16%
Autoantibodies
16%
Microangiopathy
16%
Medicine and Dentistry
Rituximab
100%
Cyclophosphamide
100%
Thrombotic Thrombocytopenic Purpura
100%
Von Willebrand Factor Cleaving Proteinase
83%
Immunosuppressive Treatment
50%
Plasma Exchange
33%
Disease
16%
Autoimmunity
16%
Metalloproteinase
16%
Cyclosporine
16%
Splenectomy
16%
Autoantibodies
16%
Prednisone
16%
Vincristine
16%
Microangiopathy
16%
Neuroscience
Cyclophosphamide
100%
Rituximab
100%
Von Willebrand Factor Cleaving Proteinase
100%
Immunosuppressive Drug
40%
Blood Plasma
40%
Immunosuppression
20%
Autoantibodies
20%
Ciclosporin
20%
Vincristine
20%
Prednisone
20%